Janssen Research & Development, Llc
Clinical trials sponsored by Janssen Research & Development, Llc, explained in plain language.
-
New hope for ulcerative colitis: phase 3 trial launches
Disease control Not yet recruitingThis study tests a new medicine called JNJ-78934804 against an existing drug (guselkumab) in 644 people with moderate to severe ulcerative colitis, a chronic condition causing colon inflammation and ulcers. The goal is to see if the new drug can bring about remission—meaning less…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 17, 2026 04:13 UTC
-
New hope for tough blood cancers: first human trial of JNJ-95804306 begins
Disease control Not yet recruitingThis early-stage study tests a new drug called JNJ-95804306 in about 280 people with blood cancers (like leukemia) that have returned or not improved after standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. The stud…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 17, 2026 04:10 UTC
-
New study tracks psoriasis patients on guselkumab for two years
Disease control Not yet recruitingThis study follows 200 adults with moderate-to-severe plaque psoriasis who have never taken biologic drugs before. Researchers will track how long participants continue taking guselkumab over two years and measure how well their skin clears up. The goal is to understand real-worl…
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 15, 2026 11:54 UTC